Clinical trial
An Open-label Extension Study to Assess the Safety and Tolerability of DDY391 in Adult Participants With Active Moderate to Severe Psoriatic Arthritis Who Have Completed Study Treatment in CDDY391A12201
NCT07923773 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started February 2027. Interventional study, Phase 2, 88 participants (estimated). Lead sponsor Novartis Pharmaceuticals. Primary measure: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs).
How it compares
59 similar trials: same condition (Arthritis, Psoriatic) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Extension Study to Assess the Safety and Tolerability of DDY391 in Adult Participants With Active Moderate to Severe Psoriatic Arthritis Who Have Completed Study Treatment in CDDY391A12201
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- February 10, 2027
- Completion date
- January 11, 2030
- Enrollment
- 88 (estimated)
- Sites
- Not reported
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: moderate to severe psoriatic arthritis
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Lead sponsor
- Novartis Pharmaceuticals
Arms
As registered; 1 arm.
| Arm | Type | Interventions |
|---|---|---|
| DDY391 | Experimental | DDY391 |
Show registry wordingParticipants will receive DDY391 | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to 56 Weeks |
Show registry wordingNumber of participants with AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs. | |
Lead sponsor's other trials
Novartis Pharmaceuticals, most recent start first.
+3,426 more trials See the organization page
Similar trials
Same condition (Arthritis, Psoriatic) and phase, most recent start first.
+54 more trials See the condition page